Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
SIGA
SellFallen FavouriteFLAGSIGA Technologies, Inc. · Healthcare · United States · $220M · Avg Vol: $2M/d
SIGA Technologies has strong value V77 and quality Q62, but momentum at M34 is well below the calibrated floor, so stage one fails.
COMPANY DESCRIPTION
SIGA Technologies, Inc. is a pharmaceutical company focused on the development and commercialization of therapeutics for biodefense and emerging infectious diseases. Its flagship product, TPOXX (tecovirimat), is an antiviral treatment for smallpox, approved in the U.S. and E.U., and procured by governments globally for strategic stockpiles. This critical biodefense asset provides SIGA with a unique and essential market position, supported by government contracts.
FINANCIAL SUMMARY (USD)
| Year | 2022 | 2023 | 2024 | 2025 | CAGR | TTM | 2026E | 2027E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 110.8M | 139.9M | 138.7M | 94.6M | -5.1% | 53.7M | 59.9M | 162.1M | 30.9% |
| EPS | 0.46 | 0.95 | 0.83 | 0.33 | -10.5% | — | 0.15 | 1.05 | 78.4% |
| Shares | 72.7M | 71.1M | 71.4M | 71.6M | -1.5% | 71.8M | — | — | — |
| Debt | 0.5M | 0.6M | 0.5M | 0.6M | 4.1% | 0.4M | — | — | — |
| Equity | 170.2M | 196.9M | 215.8M | 198.8M | 5.3% | — | — | — | — |
| Op CF | 41.6M | 94.8M | 48.8M | 43.5M | 1.5% | -20.2M | — | — | — |
| Inv CF | 0 | -21.7K | -42.5K | -0.4M | — | — | — | — | — |
| Fin CF | -46.0M | -43.4M | -43.5M | -43.6M | — | — | — | — | — |
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of SIGA are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| SIGA | SIGA Technologies, Inc.(you) | $220M | 30 | Sell |
| ORGO | Organogenesis Holdings Inc. | $224M | 29 | Sell |
| DERM | Journey Medical Corporation | $211M | 24 | Sell |
| AKBA | Akebia Therapeutics, Inc. | $243M | 17 | Strong Sell |
| CL.CN | Cresco Labs Inc. | $291M | 43 | Hold |
| CPIX | Cumberland Pharmaceuticals Inc. | $127M | 38 | Hold |
| LFCR | Lifecore Biomedical, Inc. | $172M | 16 | Strong Sell |
| VREO.CN | Vireo Growth Inc. | $552M | 33 | Sell |
| TKNO | Alpha Teknova, Inc. | $382M | 44 | Hold |
| JUSH.CN | Jushi Holdings Inc. | $110M | 43 | Hold |
Peer medians: ROE -30.8% · P/E 27.0x · Gross margin 58.3%